The US Clinical Research Market Outlook to 2017 – Led by Aging Population ... DigitalJournal.com The new drugs such as laquinimod, teriflunomide and dimethyl fumarate, and three mAbs— alemtuzumab, daclizumab and rituximab are anticipated to mask the effects and remit the occurrence of multiple sclerosis” - according to the research report 'The US ... |
